Generali Investments CEE, investicni spolecnost, a.s.
Position in NVS — Novartis AG
CIK 2047540
PRAGUE, 2N
Position in NVS
as of Jun 30, 2026
· filed Jul 13, 2026
Position Value
$1,880,640
+$47,640 QoQ
Shares Held
12,000
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#446
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Generali Investments CEE, investicni spolecnost, a.s. holds $56,299,358 across 12 Drug Manufacturers - General names. NVS ranks #10 (3.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
8,184 | $9,816,135 | |
| 2 | BIIB |
Biogen Inc.
|
43,552 | $9,409,845 | |
| 3 | ABBV |
AbbVie Inc.
|
35,651 | $8,971,217 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
53,896 | $6,809,220 | |
| 5 | JNJ |
Johnson & Johnson
|
17,556 | $4,458,697 | |
| 6 | AMGN |
Amgen Inc
|
12,193 | $4,415,329 | |
| 7 | MRK |
Merck & Co., Inc.
|
27,981 | $3,595,558 | |
| 8 | AZN |
Astrazeneca PLC
|
13,830 | $2,622,444 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,880,640 | 12,000 | Shares | Sole | 2026-07-13 | |
| 2026-03-31 | $1,833,000 | 12,000 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $1,654,440 | 12,000 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $1,538,880 | 12,000 | Shares | Sole | 2025-10-14 | |
| 2025-06-30 | $1,452,120 | 12,000 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $1,337,760 | 12,000 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $1,167,720 | 12,000 | Shares | Sole | 2025-02-07 | |
| No filing history on record for this holder in this stock. | ||||||